{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.36","upperLimit":"11.07","value":"9.5"},{"groupId":"OG001","lowerLimit":"7.43","upperLimit":"14.75","value":"9.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"description":"PFS was defined as the time from start of treatment to the earliest documented disease progression (PD) or death. Metastatic BCC - PD: ≥ 20% increased sum of the longest diameter (SLD) of targets from nadir, or 1 or more new lesions. Locally advanced BCC - PD: any of: (1) ≥ 20% increased SLD from nadir (radiography or externally visible dimension); (2) new ulceration; (3) new lesions (radiography or physical exam); (4) progression of non-target lesions by radiography.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.","id":"OG000","title":"Metastatic Basal-Cell Carcinoma"},{"description":"Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.","id":"OG001","title":"Locally Advanced Basal-Cell Carcinoma"}],"paramType":"MEDIAN","populationDescription":"Efficacy-evaluable population: All treated patients for whom the independent pathologist's interpretation of archival tissue or baseline biopsies was consistent with basal cell carcinoma.","reportingStatus":"POSTED","timeFrame":"From the initial dose of study drug until the earliest documented disease progression (PD) or death (up to the clinical cutoff date of 28 November 2011, up to 2 years, 5.5 months)","title":"Progression-Free Survival (PFS) Determined by the Independent Review Facility","type":"SECONDARY","unitOfMeasure":"Months"}